Related Experiment Video
Updated: Jun 9, 2026

Measurement of Fatty Acid β-Oxidation in a Suspension of Freshly Isolated Mouse Hepatocytes
Published on: September 9, 2021
Biochemical effects of methotrexate in isolated hepatocytes in relation to its steatogenic activity
D Deboyser1, F Goethals, M Roberfroid
1Unité de Biochimie Toxicologique et Cancérologique, Université Catholique de Louvain, UCL 7369, Avenue Mounier 73, 1200 Brussels, Belgium.
Abstract:
Methotrexate (MTX) is known to induce steatosis in humans. The effect of MTX on the synthesis and secretion of triglycerides and proteins as well as on RNA synthesis were evaluated using isolated rat hepatocytes in suspension as an experimental model. MTX significantly inhibited protein synthesis (48% inhibition after 180 min) and RNA synthesis (72% inhibition after 180 min) at 10(-3)m but not at a concentration of 10(-4)m. Protein secretion was not affected by MTX at any of the concentrations tested. At 10(-3)m, but not at 10(-4)m, MTX inhibited triglyceride secretion (44% inhibition after 180 min). At both 10(-3) and 10(-4)m, MTX significantly depleted the intracellular triglyceride, and significantly inhibited total triglyceride esterification (18 and 28% inhibition at 10(-4) and 10(-3)m-MTX, respectively). These data support the hypothesis that MTX affects protein and fatty-acid metabolism.
Related Concept Videos
Phase II Reactions: Methylation Reactions
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Bioactivation and Tissue Toxicity
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Therapeutic Drug Monitoring: Affecting Factors

